Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 119 in relapsed/refractory small cell lung cancer
NCT03392064Phase 1Suspended
- Sponsor
- Amgen
- Start
- Sep 2018
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AMG-119 in small cell lung cancer (SCLC), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities at 5 years, Treatment-Emergent Adverse Events at 5 years and 3 more. Started Sep 2018; status: suspended.
02
Drugs
AMG-119
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03392064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392064.